PMID: 8593729Sep 1, 1995Paper

Myelodysplastic syndrome presenting as cutaneous vasculitis

Clinical and Experimental Dermatology
B F O'DonnellR Carr

Abstract

A patient presenting with cutaneous vasculitis was noted to be pancytopenic. Subsequent investigation showed a myelodysplastic syndrome (MDS)--refractory anaemia with excess of blasts. Within 3 months her MDS progressed to acute myeloid leukaemia.

References

Jan 1, 1992·Dermatology : International Journal for Clinical and Investigative Dermatology·J Luelmo-AguilarA Castells-Rodellas
Feb 1, 1992·American Journal of Hematology·J J Michiels, F J ten Kate
Sep 1, 1991·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·G FicarraE De Maio
Nov 1, 1991·Journal of Cardiovascular Pharmacology·E F SmithK M Esser
Jan 1, 1992·Journal of the American Academy of Dermatology·J A YianniasL E Gibson
Aug 1, 1991·British Journal of Haematology·J A SavigeJ C Duggan
Jan 1, 1991·British Journal of Haematology·M S DoutreJ Reiffers
Sep 1, 1990·The British Journal of Dermatology·J A McGrath, M W Greaves
Aug 1, 1990·British Journal of Haematology·A J WarrenI A Reilly
Sep 1, 1990·Cleveland Clinic Journal of Medicine·P F RockleyJ K Brydon
Mar 1, 1990·British Journal of Haematology·A R GreenD P Bentley
Jul 1, 1990·British Journal of Haematology·A PagliucaG J Mufti
May 1, 1986·British Journal of Haematology·G J MuftiJ A Copplestone
May 1, 1983·British Journal of Haematology·A G BynoeB E Roberts
Sep 1, 1984·British Journal of Haematology·S TakagiY Miura
Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
Jan 1, 1993·Clinics in Dermatology·R Kurzrock, P R Cohen
Sep 1, 1993·American Journal of Clinical Pathology·T A Longacre, B R Smoller
Jan 1, 1993·Leukemia & Lymphoma·J A SavigeJ C Duggan

❮ Previous
Next ❯

Citations

Oct 16, 2001·La Revue de médecine interne·J J MorandJ J Grob
Apr 28, 2017·Hematological Oncology·Claudio Fozza

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.